I must admit, I had assumed as much. It would make the most sense given it maximises the potential interest of BPs when it comes to assessing the possible synergies with their own drugs. I imagine it also wouldn't cost much or take much longer to do so as well.
This could also give them a competitive advantage in a highly competitive PD-1 market, whereby they could maximise share of PD-1 market whilst charging for Zantrene as a combination therapy. Undercut on PD-1 inhibitor cost, charging full value for FTO inhibitor.
Zantrene could be used to monopolise the PD-1 market, a market with a potential value of $77bn in 2026.
Speculative M&A Transaction Analysis, page-621
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.020(1.27%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.53 | $201.2K | 127.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1817 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 2658 | 2 |
View Market Depth
| Last trade - 15.06pm 16/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |